Skip to content
Aminoscope
← Research
Longevity

Enclomiphene dosage: what the trials actually used

Studied as a once-daily oral dose of 6.25 to 25 mg, with 25 mg reaching testosterone comparable to a gel — but there's no FDA-approved schedule, and the product is compounded.

Priya Anand7 min read
Enclomiphene doses studied in trials: 6.25, 12.5 and 25 mg once dailynormal testosterone rangetestosterone6.25 mg12.5 mg25 mg · top dose studiedSTUDIED DOSES · 6.25 / 12.5 / 25 MG ONCE DAILY

There is no official enclomiphene dose, and any honest dosing article has to start there. Because enclomiphene was never FDA-approved for men, there is no manufacturer label setting a standard dose, no titration schedule, and no regulated product to anchor one. What exists instead is a set of clinical trials that tested specific oral doses — and those trials are the only real guide to what was studied and what it did. For the full evidence base behind the drug, see our enclomiphene evidence monograph.

The doses that were actually studied

The pharmacokinetic and dose-ranging work used three once-daily oral doses of enclomiphene citrate (developed as Androxal): 6.25 mg, 12.5 mg and 25 mg, taken daily and compared against a transdermal testosterone gel.[1] All three doses raised total testosterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) — the drug worked across the range, not just at the top.[1] A later systematic review of selective estrogen receptor modulators in men likewise describes enclomiphene being given at 12.5–25 mg daily across the pooled studies.[5] So the practical window the literature actually explored is roughly 6.25 to 25 mg, once a day, by mouth.

  1. Low

    6.25 mg daily

    Lowest dose in the pharmacokinetic study; still raised testosterone, LH and FSH.

  2. Mid

    12.5 mg daily

    Middle of the studied range; the lower of the two Phase III doses.

  3. Top

    25 mg daily

    Highest dose studied; reached 604 ± 160 ng/dL total testosterone at six weeks.

The dose range studied across enclomiphene's clinical program — all once-daily and oral. These are studied doses, not an approved schedule.

What the top dose produced

At the 25 mg dose, after six weeks of continuous daily use, mean total testosterone reached 604 ± 160 ng/dL — statistically indistinguishable from the 500 ± 278 ng/dL reached on transdermal testosterone in the same study (p = 0.23).[1]The headline is not that enclomiphene beat the gel; it is that an oral pill matched it on the number that shows up on a lab report, while doing so through the body’s own production rather than replacement.

  • Enclomiphene 25 mg, 6 weeks604 ng/dL
  • Transdermal testosterone, 6 weeks500 ng/dL
Total testosterone after six weeks at the 25 mg dose versus transdermal testosterone — the difference was not statistically significant (p = 0.23). Units: ng/dL. Phase II PK/dose-ranging RCT — PMID 23875626

A note on units, because the trials are easy to misread: this 604 figure is in ng/dL, from the dose-ranging study.[1] A separate six-month trial reported testosterone in pg/dL and is not directly comparable — there, enclomiphene moved men from a baseline of 165 ± 66 pg/dL to 525 ± 256 pg/dL, again close to the gel.[2] Same direction, different unit; always check which one a source is quoting.

Once daily, oral, and how fast it works

Enclomiphene was given as a once-daily oral dose — no injections, no reconstitution.[1] Testosterone and LH began rising within about two weeksof starting, and the hormonal effect persisted for at least a week after stopping, suggesting the response does not collapse the instant a dose is missed.[1] The pharmacokinetics also showed a daily rhythm in testosterone — higher in the morning, dipping mid-day, rising again at night — rather than a flat line.[1] Notably, enclomiphene did not measurably disturb thyroid hormones, cortisol, lipids or bone markers in that study, though both it and the gel lowered IGF-1.[1]

Why there is no “recommended” dose

This is the part the compounding-pharmacy marketing tends to gloss over. Enclomiphene was developed as Androxal by Repros Therapeutics, and its New Drug Application was not approved for male hypogonadism.[4] Clomiphene, its parent compound, is FDA-approved only for ovarian dysfunction in women, which makes any use in men inherently off-label.[3] Without an approval, there is no official maintenance dose, no titration guidance, and no quality-controlled product — the doses above are what trials tested, not a prescription a regulator has signed off on. Any specific regimen a clinic recommends is an extrapolation from this small trial base.

The honest bottom line

If you strip it to what the evidence supports: enclomiphene was studied as a once-daily oral dose between 6.25 and 25 mg, with 25 mg the top dose and the one that reached testosterone levels comparable to a gel.[1] It acted within about two weeks and through the body’s own hormonal axis. But there is no approved dose, the trials were small and short, and the real-world product is compounded and unverified. Dosing decisions belong with a clinician who can monitor testosterone, LH, FSH and estradiol — not with a number copied off a forum. For how the drug compares with the alternatives, see enclomiphene vs TRT, enclomiphene vs clomid, and what to expect on the side-effects side.

Reviewed against primary sources by the Aminoscope desk

Sources

  1. [1] Wiehle R, Cunningham GR, Pitteloud N, et al. (2013). Testosterone restoration by enclomiphene citrate in men with secondary hypogonadism: pharmacodynamics and pharmacokinetics. BJU Int. PMID 23875626
  2. [2] Kaminetsky J, Werner M, Fontenot G, Wiehle RD. (2013). Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. PMID 23530575
  3. [3] Rodriguez KM, Pastuszak AW, Lipshultz LI. (2016). Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opin Pharmacother. PMID 27337642
  4. [4] Earl JA, Kim ED. (2019). Enclomiphene citrate: a treatment that maintains fertility in men with secondary hypogonadism. Expert Rev Endocrinol Metab. PMID 31063005
  5. [5] Tienforti D, Castellini C, Di Giulio F, et al. (2023). Selective estrogen receptor modulators for functional hypogonadism in men: a systematic review and meta-analysis. Andrology. PMID 36604313

More in Longevity